Opiant Pharmaceuticals (OPNT) Releases Quarterly Earnings Results
Opiant Pharmaceuticals (NASDAQ:OPNT) posted its quarterly earnings data on Monday. The technology company reported ($2.77) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.19) by ($1.58), Bloomberg Earnings reports. Opiant Pharmaceuticals had a return on equity of 278.86% and a net margin of 35.68%.
Opiant Pharmaceuticals (NASDAQ OPNT) traded up $0.80 during trading on Tuesday, reaching $31.36. The company’s stock had a trading volume of 31,300 shares, compared to its average volume of 35,379. Opiant Pharmaceuticals has a 12-month low of $5.00 and a 12-month high of $51.90. The company has a market cap of $62.28, a price-to-earnings ratio of 10.57 and a beta of -2.33.
A number of research analysts have weighed in on OPNT shares. ValuEngine downgraded Opiant Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. TheStreet cut Opiant Pharmaceuticals from a “b” rating to a “c+” rating in a research report on Friday, November 24th.
Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).
Receive News & Ratings for Opiant Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.